Postmarketing Requirements Will Be "Studies" Unless "Trials" Are Needed, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft guidance lays out the FDAAA-mandated distinction, but also suggests that the agency continues to be much more comfortable with clinical trials than observational studies.
You may also be interested in...
Registries Rising: FDA Looking At TNF Inhibitors; AHRQ Updates Standards
The FDA Amendments Act of 2007 gave the agency many new safety powers and the potential for promotional restrictions and post-marketing fines have understandably received much industry attention. But FDA also appears to be drawing upon its beefed-up authority to increase use of a much older, low-tech safety effort: the patient registry
Registries Rising: FDA Looking At TNF Inhibitors; AHRQ Updates Standards
The FDA Amendments Act of 2007 gave the agency many new safety powers and the potential for promotional restrictions and post-marketing fines have understandably received much industry attention. But FDA also appears to be drawing upon its beefed-up authority to increase use of a much older, low-tech safety effort: the patient registry
Sentinel Safety Surveillance Not Ideal For Every Product, Reports Find
Before considering whether to use its nascent Sentinel safety surveillance system, FDA should see whether traditional methods might work just as well, according to two reports commissioned by the agency